- Over one-third of hospitalized individuals are in danger of suffering neurological issues
- Traditional EEGs present various challenges, including cross-contamination
- NeuroCap(TM) makes EEGs more accessible, sanitary
Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company with two FDA-cleared products, provides next-gen solutions to the neurology market. Neurological care that reduces the opportunity of cross-contamination is critically needed in the effort to combat COVID-19.
According to the CDC’s national forecast data, the United States is predicted to report a new record of COVID-19 cases, anticipated to number between 1 million and 2.3 million new cases the week ending Jan. 2, 2021 (https://ibn.fm/NveF2). A recent Chinese study documented the neurological impacts of COVID-19 on 214 patients under treatment across three hospitals, noting that 36.4% of those patients presented neurological manifestations (https://ibn.fm/OOcAx), which often calls for electroencephalogram (“EEG”) testing. That number amounts to over one-third of hospitalized individuals. The need for EEG-trained technicians to administer the anticipated tests is quickly accelerating.
Every day scientists are learning more about COVID-19. More data is needed as the world works to flatten the curve and discover long-term effects and treatments. To better understand its impact on the brain, EEGs must become more accessible.
Traditional EEGs present various challenges. A trained technician is needed to fit, monitor and record the process. The test can take between 30 to 45 minutes to administer patient and requires close proximity, within eight inches, to the infected patient. The EEG, sensors and wires, if not fully sterilized, can also be a source of contamination.
The solution is a disposable EEG headset, Brain Scientific’s NeuroCap(TM). FDA cleared, this disposable pre-gelled EEG headset has 22 electrodes and 19 active EEG channels and is fully compatible with existing amplifiers. Because it is designed for a single use, it minimizes cross-contamination. The NeuroCap takes only five minutes to apply and can be administered by any clinical staff member; trained technicians are not required.
Knowledge-based decision making during this worldwide health pandemic is vital. Acquiring that knowledge in cost-effective ways that reduce the chance of cross-contamination is possible with BRSF’s innovative NeuroCap.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.